Using ketone supplements to treat patients with acute heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized, double-blind, placebo-controlled trial investigates the efficacy of exogenous dietary ketone supplements containing 1,3-butanediol in patients hospitalized for acute heart failure (AHF). The study aims to determine if these supplements can improve clinical outcomes by enhancing organ perfusion and cardiac function. Participants will receive either the ketone supplement or a placebo over a 30-day period, with the primary hypothesis being that the ketone treatment will yield better results compared to placebo. The trial addresses a critical need for new therapies in AHF, where current treatments have not demonstrated survival benefits.

Why it matters

Who can join: the full rules

The study will enroll adult patients (≥18 years) admitted with AHF as the primary diagnosis, meeting all the following criteria:

1. Documented new or worsening symptoms due to heart failure with at least one of the following: persistent dyspnea at rest or with minimal exertion, or fatigue.
2. Objective evidence of worsening heart failure, consisting of at least two physical examination findings consistent with fluid retention and/or end-organ hypoperfusion or one physical examination finding and at least one laboratory criterion:

   a) Physical examination findings considered to be due to heart failure, including new or worsened: i. Peripheral edema ii. Increasing abdominal distention or ascites (in the absence of primary hepatic disease) iii. Pulmonary rales/crackles/crepitations iv. Increased jugular venous pressure and/or hepatojugular reflux v. S3 gallop vi. Clinically significant or rapid weight gain thought to be related to fluid retention b) Laboratory evidence of worsening HF, if obtained within 24 hours of presentation, including: i. Increased B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure. In patients with chronically elevated natriuretic peptides, an increase of \>30% above baseline should be noted.

   ii. Radiological evidence of pulmonary congestion iii. Echocardiographic criteria include: Dilated inferior vena cava with minimal collapse on inspiration; decreased left ventricular outflow tract (LVOT) minute stroke distance (velocity time integral \[VTI\]); septal or lateral E/e' \>15 or \>12, respectively; D-dominant pulmonary venous inflow pattern.

   iv. Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure ≥18 mmHg, central venous pressure ≥12 mmHg, or a cardiac index \<2.2 L/min/m2
3. Treatment with at least 40 mg of intravenous furosemide or its equivalent and/or intravenous vasoactive drugs and/or inotropic drugs.
4. An LVEF of ≤35% is required, measured during the present hospitalization.
5. Participants must present with elevated levels of natriuretic peptides, specifically NT-proBNP ≥600 pg/mL or BNP ≥150 pg/mL. For those in atrial fibrillation at the time of inclusion, NT-proBNP levels must be ≥900 pg/mL or BNP ≥225 pg/mL.

The enrollment window extends to the first five days of the hospital stay.

Exclusion Criteria:

1. Current hospitalization for AHF triggered by significant arrhythmia (atrial fibrillation/flutter with sustained ventricular response \>110 beats per minute, clinically significant bradycardia, or sustained ventricular tachycardia)
2. Cardiogenic shock in INTERMACS level 1 or 2 (i.e. unstable hemodynamics despite inotropic/vasopressor therapy)
3. Likelihood or current use of mechanical circulatory support
4. Recent cardiac surgery within 3 days
5. Ongoing severe infection or sepsis, severe anemia, acute exacerbation of chronic obstructive pulmonary disease, pulmonary embolism, or cerebrovascular accident
6. Significant primary valvular disease (hemodynamically severe uncorrected primary cardiac valvular disease)
7. Planned implantation of a cardiac resynchronization therapy device
8. eGFR \<15 mL/min/1.73 m2 during current hospitalization (unless ongoing continuous renal replacement therapy) or recurring dialysis
9. Known obstructive hypertrophic cardiomyopathy, congenital heart disease, acute mechanical cause of acute heart failure (e.g., papillary muscular rupture), acute myocarditis, or constrictive pericarditis according to the treating physician
10. Type 1 diabetes
11. Advanced liver disease (Child-Pugh class C)
12. Dementia or other cognitive disorder making the patient unable to give informed consent
13. Pregnancy or breastfeeding
14. Inability to intake oral substances or severe dysphagia
15. Significant gastrointestinal disease (i.e. severe inflammatory bowel disease or gastric ulcer)
16. Adherent to a ketogenic diet within 30 days of enrollment
17. Awaiting cardiac transplantation
18. Very severe lung disease and/or treatment with continuous home oxygen therapy
19. Major comorbidity, medical condition, or health issue that, according to the investigator's judgment, would hinder the participant's capacity to engage in or successfully finish the study

Where it's running

• Department of Cardiology, Aarhus University Hospital
  Aarhus N, Denmark Recruiting
• Department of Cardiology, Herlev-Gentofte Hospital
  Copenhagen, Denmark Recruiting
• Department of Cardiology, Gødstrup Hospital, Herning, Denmark
  Herning, Denmark Recruiting
• Department of Cardiology, Copenhagen University Hospital - Amager and Hvidovre Hospital
  Hvidovre, Denmark Recruiting
• Department of Cardiology, Viborg Hospital
  Viborg, Denmark Recruiting
• Department of Cardiology, Aalborg University Hospital
  Aalborg, Denmark Not yet recruiting

Study contacts

• Principal investigator: Kristoffer Berg-Hansen, MD, PhD — Department of Cardiology, Aarhus University Hospital
• Study coordinator: Kristoffer Berg-Hansen, MD, PhD
• Email: krisbe@rm.dk
• Phone: +4560540700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comprehensive clinical rule to diagnose acute heart failure in the emergency department

  A prospective study tests a combined clinical rule using patient data, a point-of-care NT-proBNP test, an 8-point lung ultrasound, and bedside echo to quickly diagnose acute heart failure in adults with new or worsening symptoms.

  Recruiting Chinese University of Hong Kong · Hong Kong and 2 other locations · NCT07754084

• Disrupted congestion in acute heart failure: can ultrasound at discharge predict readmission and death

  This study tests whether ultrasound checks of congestion at discharge can predict which patients with acute heart failure are more likely to be readmitted or die within 90 days.

  Recruiting University of Aarhus · Aarhus and 2 other locations · NCT07682298

• Pre-discharge Flu Vaccine for patients with acute heart problems

  This trial tests whether giving an influenza vaccine within 24 hours before hospital discharge helps patients who were treated for acute heart issues stay healthier this season.

  Recruiting Phase 4 Wroclaw Medical University · Wroclaw · NCT07617376

• Acute Heart Failure: How a Quantitative ECG Helps Clinicians

  This study tests whether quantitative ECG (QCG) measurements can reveal useful patterns in adults hospitalized with acute heart failure.

  Recruiting Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07601022

• Urinary Sodium and Chloride Changes and Fluid Overload in Acute Heart Failure

  This study tests whether tracking urinary sodium and chloride during hospitalization can reflect congestion removal and predict short-term outcomes in adults with acute heart failure treated with IV diuretics.

  Recruiting Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Olot, Girona and 3 other locations · NCT07597512

• Training medical residents to use the Venous Excess Ultrasound (VExUS) score for bedside volume assessment

  This project tests whether in-person or remote training better teaches medical residents to use the VExUS ultrasound score for bedside volume checks in patients with acute heart failure.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT07541768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.